

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants :Toshihiro TANAKA et al.

Group Art Unit : 1634

Appl. No. : 10/523,723

Examiner : Katherine Salmon

I.A. Filed : August 8, 2003

Confirmation No. : 1079

For : METHOD OF JUDGING INFLAMMATORY DISEASE

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir :

In accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98,

Applicants hereby submit this Supplemental Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.

Applicants direct the Examiner's attention to the documents listed in the attached PTO-1449 Form. Applicants note that the Office Action for Japanese Application No. 2004-527375, which is a corresponding application of the above-referenced application, and the documents cited therein, were submitted in an Information Disclosure Statement filed on October 20, 2009 or on March 1, 2006. Applicants submit herewith the English translation of the relevant portion of the Office Action for Japanese Application No. 2004-527375, as well as another copy of the Office Action for Japanese Application No. 2004-527375.


Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed copy of the PTO-1449 Form with the next official

communication. If additional copies of any other documents are needed, the Examiner is requested to contact the undersigned.

Applicants note that this Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance. Applicants hereby certify that no item of information in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application more than three months prior to the filing of this Information Disclosure Statement 37 C.F.R. § 1.97 (e)(1). Thus, no fee is believed necessary to ensure consideration of the submitted material. If a fee is required for any reason, then this should be considered express authorization to charge any necessary fee for consideration of this Information Disclosure Statement to Deposit Account No. 19-0089.

Should the Examiner have any questions or comments regarding this matter, the undersigned may be contacted at the below-listed telephone number.

Respectfully Submitted,  
Toshihiro TANAKA et al.



Bruce H. Bernstein

Reg. No. 29,027 42,920

December 8, 2009  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191